NLRP3 and atherosclerosis: There are a plethora of articles, reviews, and clinical trials dedicated to exploring inflammation modulators/biomarkers and pro-/anti-inflammatory (such as IL-1, IL-6, IL-18, TNF-α and CRP, PTX3, and adhesion molecules) and signaling pathways (such as NLRP3 inflammasome, NF-κB), which are implicated in endothelium dysfunction and, as a result, in atherosclerosis.